Seattle, United States
InduPro, established in 2022, operates at the forefront of the Biotechnology and Health and Wellness sectors. Based in the United States, the company embodies the ethos of "Proximity by design" through its pioneering cell-surface platform technologies.
At the core of InduPro's innovation is the ability to redefine and manipulate protein interactions, stepping beyond conventional signaling paradigms. Their platforms ingeniously combine inherent protein proximities on cell surfaces with the capacity to induce specific protein pairings. This approach facilitates the creation of novel signaling pathways and logic gates, setting new standards in therapeutic development.
The company's robust potential was underscored by its recent $85.00M Series A funding on 13 June 2024, backed by notable investors such as Emerson Collective, The Column Group, Euclidean Capital, MRL Ventures Fund, and Vida Ventures. This substantial investment signals strong confidence in InduPro's transformative impact on healthcare.
